-
公开(公告)号：US20190277861A1
公开(公告)日：2019-09-12
申请号：US16420385
申请日：2019-05-23
Applicant: Roche Diagnostics Operations, Inc.
Inventor： Johann Karl , Ursula-Henrike Wienhues-Thelen , Dirk Block , Christian Zaugg , Hans-Peter Brunner , James Januzzi , Andre Ziegler , Julian Braz , Thomas Dieterle , Edelgard Kaiser
IPC: G01N33/68
Abstract: The present disclosure relates to a method for diagnosing and/or grading diastolic dysfunction or at least one structural or functional abnormality associated with diastolic dysfunction. The method involves measuring the level of IGFBP7 (Insulin like growth factor binding protein 7) and, optionally, the level of at least one further marker in a patient suffering from heart failure, and comparing the level to a reference level. Further envisaged is a method of monitoring diastolic function in a patient suffering from heart failure. Also encompassed by the present disclosure are kits and devices adapted to carry out the method of the present invention.
-
2.发明申请公开(公告)号：US20190353666A1
公开(公告)日：2019-11-21
申请号：US16217612
申请日：2018-12-12
Applicant: Roche Diagnostics Operations, Inc.
Inventor： Herbert Andres , Dirk Block , Johann Karl , Peter Kastner , Ursula-Henrike Wienhues-Thelen , Roberto Latini , Serge Masson , Andre Ziegler , Edelgard Kaiser , Stefan Palme , Markus Thomas , Simona Barlera
IPC: G01N33/68
Abstract: The present disclosure relates to a method for predicting the risk of recurrence of Atrial Fibrillation in a subject based on determining the amount of the biomarker Angiopoietin-2 (Ang-2) and optionally of at least one further biomarker in a sample from the subject. The present disclosure also contemplates a method of diagnosing Atrial Fibrillation in a subject suspected to suffer from Atrial Fibrillation based on determining the amount of the biomarker Angiopoietin-2 (Ang-2) and optionally of at least one further biomarker in a sample from the subject. Further envisaged are devices adapted to carry out the method of the present disclosure.
-
公开(公告)号：US20170227552A1
公开(公告)日：2017-08-10
申请号：US15581587
申请日：2017-04-28
Applicant: Roche Diagnostics Operations, Inc.
Inventor： Roberto Latini , Serge Masson , Dirk Block , Christian Zaugg , Thomas Dieterle , Edelgard Kaiser , Johann Karl , Vinzent Rolny , Ursula-Henrike Wienhues-Thelen
IPC: G01N33/68
Abstract: The present invention relates to a method for predicting the risk of a subject of rapidly progressing to chronic heart failure and/or of hospitalization due to chronic heart failure and/or death. The method is based on the determination of at least one biomarker selected from the group consisting of a BNP-type peptide, IGFBP7 (IGF binding protein 7), a cardiac Troponin, soluble ST2 (sST2), FGF-23 (Fibroblast Growth Factor 23), and Growth Differentiation Factor 15 (GDF-15), in a sample of a subject. The method may further encompass the assessment of the presence or absence of (i) abnormal midwall fractional shortening or (ii) left ventricular hypertrophy. Further envisaged by the present invention are devices adapted to carry out the present invention.
-
4.发明授权公开(公告)号：US11644472B2
公开(公告)日：2023-05-09
申请号：US16217612
申请日：2018-12-12
Applicant: Roche Diagnostics Operations, Inc.
Inventor： Herbert Andres , Dirk Block , Johann Karl , Peter Kastner , Ursula-Henrike Wienhues-Thelen , Roberto Latini , Serge Masson , Andre Ziegler , Edelgard Kaiser , Stefan Palme , Markus Thomas , Simona Barlera
CPC classification number: G01N33/6887 , G01N33/6893 , G01N2800/326
Abstract: A method for predicting the risk of recurrence of Atrial Fibrillation in a subject based on measuring the amount of the biomarker Angiopoietin-2 (Ang-2) and optionally of at least one further biomarker in a sample from the subject is described. Also described is a method of diagnosing Atrial Fibrillation in a subject suspected to suffer from Atrial Fibrillation based on measuring the amount of the biomarker Angiopoietin-2 (Ang-2) and optionally of at least one further biomarker in a sample from the subject. Also described are devices adapted to carry out the method of the present disclosure.
-
Patent Agency Ranking
公开(公告)号：US11047866B2
公开(公告)日：2021-06-29
申请号：US16420385
申请日：2019-05-23
Applicant: Roche Diagnostics Operations, Inc.
Inventor： Johann Karl , Ursula-Henrike Wienhues-Thelen , Dirk Block , Christian Zaugg , Hans-Peter Brunner , James Januzzi , Andre Ziegler , Julian Braz , Thomas Dieterle , Edelgard Kaiser
Abstract: Presented is a method for diagnosing and/or grading diastolic dysfunction or at least one structural or functional abnormality associated with diastolic dysfunction. The method involves measuring the level of IGFBP7 (Insulin like growth factor binding protein 7) and, optionally, the level of at least one further marker in a patient suffering from heart failure, and comparing the level to a reference level. Further envisaged is a method of monitoring diastolic function in a patient suffering from heart failure. Also described are kits and devices adapted to carry out the method.
-
公开(公告)号：US20170010283A1
公开(公告)日：2017-01-12
申请号：US15274533
申请日：2016-09-23
Applicant: Roche Diagnostics Operations, Inc.
Inventor： Johann Karl , Ursula-Henrike Wienhues-Thelen , Dirk Block , Christian Zaugg , Hans-Peter Brunner , James Januzzi , Andre Ziegler , Julian Braz , Thomas Dieterle , Edelgard Kaiser
IPC: G01N33/68
CPC classification number: G01N33/6893 , G01N33/6887 , G01N2333/47 , G01N2800/325
Abstract: The present invention relates to a method for diagnosing and/or grading diastolic dysfunction or at least one structural or functional abnormality associated with diastolic dysfunction. The method comprises measuring the level of IGFBP7 (Insulin like growth factor binding protein 7) and, optionally, the level of at least one further marker in a patient suffering from heart failure, and comparing the level to a reference level. Further envisaged is a method of monitoring diastolic function in a patient suffering from heart failure. Also encompassed by the present invention are kits and devices adapted to carry out the method of the present invention.
Abstract translation: 本发明涉及一种用于诊断和/或分级舒张功能障碍或与舒张功能障碍相关的至少一种结构或功能异常的方法。 该方法包括测量患有心力衰竭的患者中IGFBP7（胰岛素样生长因子结合蛋白7）的水平和任选地至少一个其他标记物的水平，并将该水平与参考水平进行比较。 进一步设想的是监测患有心力衰竭的患者的舒张功能的方法。 本发明还包括适用于实施本发明方法的试剂盒和装置。
-
公开(公告)号：US20200371114A1
公开(公告)日：2020-11-26
申请号：US16721112
申请日：2019-12-19
Applicant: Roche Diagnostics Operations, Inc.
Inventor： Roberto Latini , Serge Masson , Dirk Block , Christian Zaugg , Thomas Dieterle , Edelgard Kaiser , Johann Karl , Vinzent Rolny , Ursula-Henrike Wienhues-Thelen
IPC: G01N33/68
Abstract: The present invention relates to a method for predicting the risk of a subject of rapidly progressing to chronic heart failure and/or of hospitalization due to chronic heart failure and/or death. The method is based on the determination of at least one biomarker selected from the group consisting of a BNP-type peptide, IGFBP7 (IGF binding protein 7), a cardiac Troponin, soluble ST2 (sST2), FGF-23 (Fibroblast Growth Factor 23), and Growth Differentiation Factor 15 (GDF-15), in a sample of a subject. The method may further encompass the assessment of the presence or absence of (i) abnormal midwall fractional shortening or (ii) left ventricular hypertrophy. Further envisaged by the present invention are devices adapted to carry out the present invention.
-
公开(公告)号：US10557858B2
公开(公告)日：2020-02-11
申请号：US15581587
申请日：2017-04-28
Applicant: Roche Diagnostics Operations, Inc.
Inventor： Roberto Latini , Serge Masson , Dirk Block , Christian Zaugg , Thomas Dieterle , Edelgard Kaiser , Johann Karl , Vinzent Rolny , Ursula-Henrike Wienhues-Thelen
Abstract: Described is a method for predicting the risk of a subject of rapidly progressing to chronic heart failure and/or of hospitalization due to chronic heart failure and/or death. The method is based on the determination of at least one biomarker selected from B-type natriuretic peptide (BNP) or N-terminal pro B-type natriuretic peptide (NT-proBNP), IGFBP7 (IGF binding protein 7), a cardiac Troponin, soluble ST2 (sST2), FGF-23 (Fibroblast Growth Factor 23), and Growth Differentiation Factor 15 (GDF-15), in a sample of a subject along with the assessment of the presence or absence of (i) abnormal midwall fractional shortening or (ii) left ventricular hypertrophy.
-
公开(公告)号：US10345315B2
公开(公告)日：2019-07-09
申请号：US15274533
申请日：2016-09-23
Applicant: Roche Diagnostics Operations, Inc.
Inventor： Johann Karl , Ursula-Henrike Wienhues-Thelen , Dirk Block , Christian Zaugg , Hans-Peter Brunner , James Januzzi , Andre Ziegler , Julian Braz , Thomas Dieterle , Edelgard Kaiser
Abstract: Disclosed herein is a method for diagnosing and/or grading diastolic dysfunction or at least one structural or functional abnormality associated with diastolic dysfunction. The method involves measuring the level of IGFBP7 (Insulin like growth factor binding protein 7) and, optionally, the level of at least one further marker in a patient suffering from heart failure, and comparing the level to a reference level. Also disclosed is a method of monitoring diastolic function in a patient suffering from heart failure, and kits and devices for performing the method.
-
-
-
-
-
-
-
-
Search Results
9
records
(took 0.02 seconds)
